C-Bridge hands Nu­ance Biotech $35M, open­ing doors to more Chi­na li­cens­ing deals

Chi­na’s pow­er­house pri­vate eq­ui­ty play­er C-Bridge Cap­i­tal is dish­ing out $35 mil­lion to ex­per­i­ment with a new part­ner­ship mod­el.

Its part­ners at Nu­ance Biotech an­nounced a deal with Paci­ra Phar­ma that gave them de­vel­op­ment and com­mer­cial­iza­tion rights of Ex­par­el in Chi­na. What went un­men­tioned at the time was the role C-Bridge played, iden­ti­fy­ing the op­por­tu­ni­ty and fa­cil­i­tat­ing the pact.

That deal makes sense, says Nu­ance CEO Mark Lot­ter, be­cause the non-opi­oid pain drug fits right with their fo­cus in the sur­gi­cal space.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.